The localization of the MST1/2 and LATS1/2, whether it is cytoplasmic or nuclear, may impact the efficacy of the neoadjuvant therapy in breast cancer; being protective when expressed in the cytoplasm of tumor cells and in tumor-infiltrating lymphocytes. Here, LATS1 is linked to neoplasm.